Note: This is the third article of a three-part series .

Real-world evidence (RWE) plays a crucial role in supporting the benefits of one drug over another in debates that play out on the boards and committees overseeing hospital and payer formularies. It influences how much pharmaceutical companies can charge for their drugs and which ones are covered by payers. RWE also shows how treatments perform in routine clinical settings. It includes measurable improvements in patient outcomes, enhanced quality of life, and reductions in healthcare costs. This allows companies to make more informed decisions between pricing strategies and market access goals.

RWE also includes data that go beyond the efficacy data from controlled trials.

If pharma companies are to ensure the effectiveness o

See Full Page